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Abstract A 55-year-old woman developed an atraumatic
sternum fracture during treatment with alendronate for
osteoporosis. The woman received alendronate 70 mg in
combination with cholecalciferol 5600 IU once weekly, as
well as nonsteroidal anti-inflammatory drugs. After 4 years
of treatment, following a dorsal flexion with no direct
thoracic trauma, the patient suffered a fracture of the
sternum, with an X-ray revealing sternal body fracture.
This fracture was seen to be transverse, noncomminuted
and without displacement. Magnetic resonance imaging
was carried out to rule out the presence of either a patho-
logical fracture or a fracture resulting from osteoporotic
fragility, and showed a triple sternal fracture involving the
body, as well as the upper and lower manubrium of the
sternum. This fracture presented the features of an atypical
femur fracture, except for the location. The alendronate and
cholecalciferol combination was discontinued and deno-
sumab was prescribed. After the withdrawal of alendronate,
the patient showed clinical improvement, with a decrease
in pain, and is currently having routine checkups. The
causality algorithm of the Spanish Pharmacovigilance
System shows a score of 5, indicating a possible
relationship between the patient’s sternum fracture and her
use of the suspect drug (Naranjo scale 6 = probable).
Key Points
Long-term treatment with bisphosphonates could
induce atypical fractures in anatomical locations
other than the femur.
Bisphosphonate treatment should be reconsidered in
patients after long-term use.
All suspected adverse drug reactions must be
reported to the pharmacovigilance systems in order
to detect potential alarm signals related to drug use.
Introduction
Bisphosphonates are synthetic drugs that bind to bone
hydroxyapatite crystals and inhibit the action of osteo-
clasts, thus preventing both in vitro and in vivo bone
resorption. Approximately 50% of the drug is deposited in
the bone; however, the time it stays in the bone or the
potential long-term effects are not accurately known.
Prolonged bisphosphonate therapy has been linked to
atypical fractures. The risk seems to be related to the
suppression of bone turnover, which, in turn, may favour
certain types of fractures [1]. Thus far, the fractures that
have been described as bisphosphonate therapy-related
atypical fractures share a certain number of clinical and
radiological features, i.e. they are likely to be located at the
subtrochanteric area of the femur; a previous trauma cannot
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be found or trauma is minimal; they are noncomminuted,
transverse or slightly oblique; and they may be either
complete or incomplete fractures [2]. To our knowledge,
this is the first report of a sternum fracture that was likely
to be related to bisphosphonate therapy. In addition, it is
the first case that occurred with no trauma and involving a
nonelderly female patient that has been reported to the
Spanish Pharmacovigilance System.
Case Report
The patient was a 55-year-old female with a history of
smoking since the age of 16 years (20 cigarettes/day), with
no other cardiovascular risk factors and presenting with a
body mass index (BMI) of 25 kg/m2. She reached meno-
pause at the age of 53 years. The patient had no other
concomitant conditions, and her medical record indicated
that she had not been previously treated with corticoids.
In 2010, following an intense lumbar effort, the patient
experienced severe lumbar pain. Lumbar X-ray and
computed tomography (CT) revealed D11 fracture and L1
partial collapse. Femoral and lumbar dual energy X-ray
absorptiometry (DEXA) densitometry showed a total
femur bone density of 0.770 g/cm2 (T-score 1.9; Z-score
1.6) and a bone mineral density on lumbar spine of
0.881 g/cm2 (T-score 2.5; Z-score 1.8), consistent with
femoral osteopenia and lumbar osteoporosis, according to
the World Health Organization (WHO) criteria. Accord-
ingly, in September 2010, the patient was prescribed a
combination of alendronate 70 mg and cholecalciferol
5600 IU once weekly, as well as nonsteroidal anti-in-
flammatory drugs. Improvement was noted and since then
periodical routine densitometry tests have been carried
out, which showed femoral and lumbar osteopenia
(Table 1). In October 2013, the patient continued to
complain of chronic dorsolumbar pain.
In April 2014, the patient felt a sensation of stabbing
pain in the sternal area while sitting up in bed, followed by
pain while moving and breathing, but no dyspnoea. She
had not suffered any external force (i.e. pushing) or trauma.
Because of these alarming symptoms, she came to the
hospital Emergency Department. Physical examination
disclosed a swollen, painful area located on the sternal
region of the body. Coronary involvement was ruled out.
Sternal X-ray revealed sternal body fracture, which was
seen to be transverse, noncomminuted and without dis-
placement. Magnetic resonance imaging (MRI) was
undertaken to rule out the presence of either a pathological
fracture or a fracture resulting from osteoporotic fragility.
MRI showed a triple sternal fracture involving the body, as
well as the upper and lower manubrium of the sternum
(Fig. 1). Pathological fracture was ruled out; however, an
old pathological fracture of the eleventh dorsal vertebra
(D11) with several vertebral collapses at D4, D7 and D8
was noted.
Metabolic study to dismiss potential secondary osteo-
porosis-related causes and tests aimed at ruling out other
bone diseases (i.e. hyperparathyroidism, hypothyroidism,
bone tumours or metastases, calcium-phosphorus metabo-
lism disorders, and vitamin D deficiency) was performed.
All these tests yielded normal results, except for vitamin D
[25 ng/L (range 30–80)]. This slight hypovitaminosis D
does not seem to be clinically relevant, and is thus insuf-
ficient to induce this kind of fracture, involving three parts
of the sternum. The results of densitometry carried out in
May 2014 were consistent with total femur osteopenia and
lumbar spine osteopenia (Table 1); therefore, other factors
that could have contributed to the development of this
fracture were ruled out. Due to suspicion of an alendronate-
related fracture, the alendronate plus cholecalciferol com-
bination was discontinued and the specialist who followed
this patient decided to prescribe denosumab. The patient
was treated with calcium and vitamin D during the entire
process.
After the withdrawal of alendronate, the patient showed
clinical improvement, with a decrease in pain, and is cur-
rently having routine checkups.
The causality algorithm of the Spanish Pharmacovigi-
lance System [3] shows a score of 5, indicating a possible
relationship between the patient’s sternum fracture and her
use of the suspect drug (Naranjo scale 6, probable).
Table 1 Densitometry results performed on the patient and the resulting diagnosis (from 2010 to 2014)
Year Femoral densitometry Lumbar densitometry
Bone mass density (g/cm2) T-score Z-score Diagnosis Bone mass density (g/cm2) T-score Z-score Diagnosis
2010 0.770 1.9 1.6 Osteopenia 0.881 2.5 1.8 Osteoporosis
2012 0.817 1.5 1.2 Osteopenia 0.955 1.9 1.1 Osteopenia
2013 0.747 2.1 1.7 Osteopenia 0.939 2.0 1.1 Osteopenia
2014 0.721 2.3 1.9 Osteopenia 0.920 2.2 1.3 Osteopenia
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Discussion
Sternal fractures are rare. They are most often caused by
severe chest traumas that usually result from car accidents,
sport lesions or violent attacks. In reviewing the literature,
we found only three cases of patients with atraumatic
fracture of the sternum. These patients presented well-
established risk factors for this type of fracture and did not
have a history of bisphosphonate therapy [4–6].
After a search of Medline, we failed to find any cases of
bisphosphonate therapy-associated atypical sternal frac-
tures; however, cases of this type of fracture in anatomical
locations other than the sternum have been published.
We also conducted a search of the Spanish Pharma-
covigilance System database (FEDRA, accessed July
2015), and encountered 121 suspected cases of bisphos-
phonate therapy-related fractures, with a total of 125
fractures, as, in some of these cases, more than one fracture
was reported for a given patient. Most of these fractures
involved the femur (n = 92), followed by fractures of the
tibia (n = 4), jaw and spine (n = 3 each), fibula (n = 2), and
ribs, sternum, radius, hip, and ankle (n = 1 each), while
anatomical location was not reported in 15 cases. The only
fracture of the sternum in the FEDRA database corre-
sponded to an 81-year-old female receiving bisphospho-
nates, which occurred because of a minimal trauma. It
should be borne in mind that all of the above were just
suspected cases because the cause–effect relationship with
bisphosphonate therapy was not established in any of the
cases. Nevertheless, the broad range of anatomical loca-
tions leads us to believe that the issue of atypical fractures
may be more complex than originally thought since atyp-
ical fractures presumably involve locations other than the
usual, particularly other than the femur.
In the present case, the causative role of the drug cannot be
dismissed because the temporal sequence is suggestive and
we were not able to find an alternative causal explanation.
Thus, it should be noted that our patient’s fracture occurred
4 years after the commencement of alendronate therapy.
MRI findings led us to rule out a pathological fracture or a
fracture caused by sternal osteoporosis, there was no severe
direct sternal trauma (i.e. the most frequent cause for sternal
fracture), the patient was only 55 years of age, she had not
been previously treated with corticoids, and secondary bone
diseases (i.e. metabolic, neoplastic or metastatic conditions)
were ruled out, with the exception of the minor vitamin D
deficiency, for which shewas being treated. Furthermore, the
features of our case suggest biological plausibility.
Accordingly, we concluded that our patient’s sternal fracture
was likely to be related to her 4-year alendronate therapy.
Although resorption markers such as C-terminal
telopeptide of type I collagen (CTX), N-terminal telopep-
tide (NTX), and deoxypyridinoline (DPD), which are
useful for the follow-up of therapy compliance, were not
measured, our patient’s compliance was checked in her
computerised medical record. Of note, all the drugs pre-
scribed to the patient within the 4-year period of interest
were stated in her medical record.
The fracture we report herein fulfilled the clinical and
radiological features of the atypical femoral fractures,
namely lack of previous trauma, and complete or incom-
plete transverse, noncomminuted fracture in a patient pre-
viously treated with bisphosphonates. The present fracture
differs from the usual atypical fractures related to bispho-
sphonates in its location only.
Conclusions
Our patient had been treated with bisphosphonates for
4 years. Accordingly, we feel that this is a case of atypical
fracture of the sternum that has not been previously
reported in the literature, and which fulfils the well-known
criteria for the atypical fracture of the femur. It is therefore
our belief that the issue of atypical fractures is far more
complex than originally thought since our case shows that
these fractures can involve anatomical locations other than
the usual. Thus, we recommend considering the potential
diagnosis of an atypical fracture, even if it is not located on
the femur, in all patients taking bisphosphonates who
present with a new fracture. The case has been reported to
the Spanish Pharmacovigilance System.
Fig. 1 Triple sternal fracture involving the body as well as the upper
and lower manubrium of the sternum
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